Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders

Abstract

OBJECTIVE: The effects of fluoxetine and placebo on repetitive behaviors and global severity were compared in adults with autism spectrum disorders (ASDs). METHOD: Adults with ASDs were enrolled in a 12-week double-blind placebo-controlled fluoxetine trial. Thirty-seven were randomly assigned to fluoxetine (N=22) or placebo (N=15). Dosage followed a fixed schedule, starting at 10 mg/day and increasing as tolerated up to 80 mg/day. Repetitive behaviors were measured with the compulsion subscale of the Yale-Brown Obsessive Compulsive Scale; the Clinical Global Impression (CGI) improvement scale was used to rate improvement in obsessive-compulsive symptoms and overall severity. RESULTS: There was a significant treatment-by-time interaction indicating a significantly greater reduction in repetitive behaviors across time for fluoxetine than for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the fluoxetine group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: fluoxetine, 35%; placebo, 0%) and 1.8 for CGI-rated improvement in obsessive-compulsive symptoms (responders: fluoxetine, 50%; placebo, 8%). Only mild and moderate side effects were observed. CONCLUSIONS: Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating. Fluoxetine appeared to be well tolerated. These findings stand in contrast to findings in a trial of citalopram for childhood autism.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2011.10050764

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Research works printed but not linked: 2

  1. 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9 · doi:10.1002/1531-8249(199903)45:3<287::aid-ana3>3.0.co;2-9
  2. Aman MG, 1985, Am J Ment Defic, 89, 485

Cited by

See all 225

Metadata

Authors
Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., Wasserman, S., Swanson, E., & Settipani, C.
Affiliations
Albert Einstein College of Medicine (US)
Venue
American Journal of Psychiatry
Published
2012-03
Volume
169
Issue
3
Pages
292-299
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2035017299
Cited by
224
References
25
Citations by year
2026: 8 · 2025: 8 · 2024: 18 · 2023: 15 · 2022: 20 · 2021: 13 · 2020: 13 · 2019: 17 · 2018: 18 · 2017: 14 · 2016: 12 · 2015: 21 · 2014: 25 · 2013: 16 · 2012: 6
FWCI
7.63
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (U54MH066673, 1U54 MH-066673)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
fluoxetine, autism spectrum disorder, autistic adults, repetitive behavior, obsessive-compulsive symptoms, Yale-Brown Obsessive Compulsive Scale, Clinical Global Impression Scale, selective serotonin reuptake inhibitors, treatment response, drug tolerability
MeSH terms
Adolescent, Adult, Child, Child Development Disorders, Pervasive, Double-Blind Method, Female, Fluoxetine, Humans, Male, Middle Aged, Obsessive Behavior, Psychiatric Status Rating Scales, Severity of Illness Index, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Stereotypic Movement Disorder, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders. https://app.cochat.ai/papers/10.1176/appi.ajp.2011.10050764
The paper
Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., Wasserman, S., Swanson, E., & Settipani, C. (2012). A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2011.10050764

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.